As tapentadol is the only Schedule II opioid that has dual MOR and monoamine transporter mechanisms, the role of this atypical opioid should continue to be evaluated, particularly within the framework of a disinformation campaign from the manufacturer downplaying the risk of addiction [43], as well as the evolving US obesity and opioid epidemics. The gene discussed is OPRM1; the disease is obesity due to melanocortin 4 receptor deficiency.